The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to ...

About Fujirebio Fujirebio is global R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value.

Fujirebio is global R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and ...

Recent research shows up to 40% of dementia cases could be prevented. Europe needs a cross-border policy rethink to impact ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Fujirebio Diagnostics’ Lumipulse G measures the ratio of two blood proteins as a proxy for the presence of amyloid plaque in the brain. Amyloid is a sticky substance that is associated with ...